131 results
Page 6 of 7
6-K
EX-99.1
rpafqjwpk
31 Mar 21
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
7:00am
6-K
EX-99.4
8c9b3av37dwrov
31 Mar 21
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
7:00am
424B3
gaggh75du
4 Mar 21
Prospectus supplement
8:38am
6-K
EX-99.1
t4to8rar4 up
4 Mar 21
Amryt Announces Record FY 2020 Results
8:20am
6-K
EX-99.1
hrmhzjxcmoki
20 Jan 21
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6:30am
424B4
2fsco qapi
14 Jan 21
Prospectus supplement with pricing info
9:30am
F-1/A
s3f0ar
12 Jan 21
Registration statement (foreign) (amended)
12:00am
F-1
ufeze9wqsqoyna6
8 Jan 21
Registration statement (foreign)
4:58pm
DRS
x4e4t7
18 Dec 20
Draft registration statement
12:00am
6-K
EX-99.1
rpd0ea24wnra2 8v5do
17 Dec 20
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
6:15am
6-K
EX-99.1
0h3zqk
9 Dec 20
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
6:30am
6-K
EX-99.1
zpnz4tlmfboyst3hw
8 Dec 20
Amryt Announces $40m Private Placement with Leading Biotech Investors
6:05am
6-K
EX-99.1
ihoynxhox3le9e4l5
5 Nov 20
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
7:55am
6-K
EX-99.1
h2kqgvyun uhh0
29 Oct 20
Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® In Epidermolysis Bullosa
8:00am
6-K
EX-99.1
pne7rusq1 dumorfocj7
19 Oct 20
Current report (foreign)
8:00am
6-K
EX-99.1
ukrsb
15 Sep 20
Current report (foreign)
8:31am
6-K
EX-99.1
7edd664363w9
9 Sep 20
Amryt Announces Positive Top Line Results from Pivotal Phase 3 “Ease” Trial of Filsuvez(r) In Epidermolysis Bullosa
8:23am
6-K
EX-99.1
nnt590zno4ga
11 Aug 20
Notification of Cancellation of Admission to Euronext Growth
10:04am
6-K
EX-99.1
06debzea3sdtn jrb
6 Aug 20
Amryt Announces Q2 2020 Results and Issues Positive Revenue Guidance for Fy 2020
9:43am
6-K
EX-99.1
qgg2u
10 Jul 20
Current report (foreign)
9:46am